Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Air Products & Chemicals, Inc. (APD) vs Bristol-Myers Squibb Co (BMY) Price & Performance

Air Products & Chemicals, Inc.Trade
Bristol-Myers Squibb CoTrade

Price performance (Past 24H)

Key statistics

Air Products & Chemicals, Inc. vs Bristol-Myers Squibb Co — how do they compare? Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.63B), while Bristol-Myers Squibb Co trades at $63.69 (market cap $132.45B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.

APDBMY
Market Cap
$68.63B$132.45B
Sector
Basic MaterialsHealth
52-Week High
$314.19$65.89
52-Week Low
$230.42$42.60
Enterprise Value
$85.80B$166.44B
Dividend Yield
2.35%3.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Air Products & Chemicals, Inc.

Air Products and Chemicals (APD) trades at $303.44, up 1.17% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The stock shows strong analyst support with a consensus price target of $346, though high valuation ratios like a P/E of 30.86 and EV/EBITDA of 50.36 raise concerns. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance after Q3 2026 results.

The outlook is mixed: positive momentum from contract wins and earnings performance offers upside, but negative net income margins and elevated debt levels pose risks. Investors should weigh growth catalysts against financial leverage and profitability challenges.

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.

BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.

Returns comparison

Trailing returns across standard periods

About Air Products & Chemicals, Inc.

Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.

Read more on APD

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY